Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12605000584639
Ethics application status
Approved
Date submitted
13/09/2005
Date registered
4/10/2005
Date last updated
30/10/2007
Type of registration
Prospectively registered
Titles & IDs
Public title
Efficacy study of HP749, 20mg versus placebo in patients with OAB- UG058-0204
Query!
Scientific title
Efficacy study of HP749, 20mg versus placebo in patients with OAB-UG058-0204 (Over active bladders).
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
UG058-0204
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Over Active Bladders
711
0
Query!
Condition category
Condition code
Renal and Urogenital
788
788
0
0
Query!
Other renal and urogenital disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
HP749
Query!
Intervention code [1]
581
0
Treatment: Drugs
Query!
Comparator / control treatment
Placebo 12 weeks
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
1005
0
Improvement of frequency as a change (from baseline to end of the treatment) in mean number of micturitions per 24h.
Query!
Assessment method [1]
1005
0
Query!
Timepoint [1]
1005
0
Query!
Secondary outcome [1]
1894
0
The proportion of patients cured at week 12 (frequency less than 8 micturitions per day) in the 20mg twice-daily HP749 arm will be compared to the placebo arm.
Query!
Assessment method [1]
1894
0
Query!
Timepoint [1]
1894
0
Query!
Secondary outcome [2]
1895
0
Evaluation of urodynamic efficacy, in the subpopulation of patients with urodynamic abnormal parameters.
Query!
Assessment method [2]
1895
0
Query!
Timepoint [2]
1895
0
At baseline.
Query!
Secondary outcome [3]
1896
0
Safety evaluationine.
Query!
Assessment method [3]
1896
0
Query!
Timepoint [3]
1896
0
Query!
Eligibility
Key inclusion criteria
History of at least 6 months of OAB symptoms, defined as at least 8 micturitions/day, one urgency with or without incontinence episode (at least one/day) and nocturia (to wake at night > 1 time to void). Patients without medication for OAB, or with ineffective and/or unsatisfactory medication for OAB or with a history of ineffective and/or unsatisfactory medication for OAB are included in the trial (wash-out of 2 weeks is mandatory before base-line period and urodynamic examination). Prerequisites for inclusion are no previous bladder training or no current bladder training if started less than one month prior to the trial. Patients with polyuria, urodynamic stress incontinence, renal disease, or bladder outlet obstruction are excluded from the trial, as are patients having any other disease or condition (including neurological disease that could be linked to OAB symptoms) making them unsuitable for participating to the trial.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
No exclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
envelopes
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
computer generated, statified in blocks
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
6/08/2006
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
210
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Funding source category [1]
873
0
Commercial sector/Industry
Query!
Name [1]
873
0
Commercial sponsor
Query!
Address [1]
873
0
Query!
Country [1]
873
0
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
UroGene SA
Query!
Address
Query!
Country
France
Query!
Secondary sponsor category [1]
739
0
Commercial sector/Industry
Query!
Name [1]
739
0
ORION Clinical Services (Aust) Pty Ltd
Query!
Address [1]
739
0
Query!
Country [1]
739
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
2153
0
Prince of Wales Hospital
Query!
Ethics committee address [1]
2153
0
Query!
Ethics committee country [1]
2153
0
Australia
Query!
Date submitted for ethics approval [1]
2153
0
Query!
Approval date [1]
2153
0
Query!
Ethics approval number [1]
2153
0
Query!
Ethics committee name [2]
2154
0
Royal Melbourne Hospital
Query!
Ethics committee address [2]
2154
0
Query!
Ethics committee country [2]
2154
0
Australia
Query!
Date submitted for ethics approval [2]
2154
0
Query!
Approval date [2]
2154
0
Query!
Ethics approval number [2]
2154
0
Query!
Ethics committee name [3]
2155
0
Royal Brisbane & Women's Hospital
Query!
Ethics committee address [3]
2155
0
Query!
Ethics committee country [3]
2155
0
Australia
Query!
Date submitted for ethics approval [3]
2155
0
Query!
Approval date [3]
2155
0
Query!
Ethics approval number [3]
2155
0
Query!
Summary
Brief summary
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
35807
0
Query!
Address
35807
0
Query!
Country
35807
0
Query!
Phone
35807
0
Query!
Fax
35807
0
Query!
Email
35807
0
Query!
Contact person for public queries
Name
9770
0
Yvonne Egan Davidson
Query!
Address
9770
0
ORION Clinical Services Australia Pty Ltd
Level 1
141 Osborne Street
South Yarra VIC 3141
Query!
Country
9770
0
Australia
Query!
Phone
9770
0
+61 3 98671064
Query!
Fax
9770
0
+61 3 98671086
Query!
Email
9770
0
[email protected]
Query!
Contact person for scientific queries
Name
698
0
Yvonne Egan Davidson
Query!
Address
698
0
ORION Clinical Services Australia Pty Ltd
Level 1
141 Osborne Street
South Yarra VIC 3141
Query!
Country
698
0
Australia
Query!
Phone
698
0
+61 3 98671064
Query!
Fax
698
0
+61 3 98671086
Query!
Email
698
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF